<code id='2178DA9AC3'></code><style id='2178DA9AC3'></style>
    • <acronym id='2178DA9AC3'></acronym>
      <center id='2178DA9AC3'><center id='2178DA9AC3'><tfoot id='2178DA9AC3'></tfoot></center><abbr id='2178DA9AC3'><dir id='2178DA9AC3'><tfoot id='2178DA9AC3'></tfoot><noframes id='2178DA9AC3'>

    • <optgroup id='2178DA9AC3'><strike id='2178DA9AC3'><sup id='2178DA9AC3'></sup></strike><code id='2178DA9AC3'></code></optgroup>
        1. <b id='2178DA9AC3'><label id='2178DA9AC3'><select id='2178DA9AC3'><dt id='2178DA9AC3'><span id='2178DA9AC3'></span></dt></select></label></b><u id='2178DA9AC3'></u>
          <i id='2178DA9AC3'><strike id='2178DA9AC3'><tt id='2178DA9AC3'><pre id='2178DA9AC3'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:Wikipedia    - browse:976
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia